| pubmed-article:6423289 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:6423289 | lifeskim:mentions | umls-concept:C0021467 | lld:lifeskim |
| pubmed-article:6423289 | lifeskim:mentions | umls-concept:C0596873 | lld:lifeskim |
| pubmed-article:6423289 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
| pubmed-article:6423289 | lifeskim:mentions | umls-concept:C0441712 | lld:lifeskim |
| pubmed-article:6423289 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:6423289 | pubmed:dateCreated | 1984-5-2 | lld:pubmed |
| pubmed-article:6423289 | pubmed:abstractText | When human peripheral blood lymphocytes were stimulated with phytohemagglutinin in the presence of serotonin, inhibition of [3H]thymidine incorporation occurred, the most marked inhibition occurring at high (10(-3)M) serotonin concentrations. This effect could not be reversed by the addition of Interleukin 2 (IL-2)-containing supernatants. Cytofluorometric analysis showed that virtually all of the cells remained in the G0 phase (unactivated) at 24 hr while some of the cells entered the G1a and G1b phases of the cell cycle by 42 hr. The cellular production of IL-2 was not affected by serotonin, as supernatants of treated cultures contained essentially the same IL-2 titers as did control cultures. Serotonin seemed to primarily affect cell activation and had little or no effect on proliferating cells. This was further confirmed by the lack of effects of serotonin on a variety of established proliferating lymphocyte, macrophage, and fibroblast cell lines. By contrast, dose-dependent inhibition of IL-2-dependent CTLL cells occurred. Serotonin was not toxic even at 10(-3) M concentrations. A marked decrease in IL-2 receptors and a change in their distribution on responder cells was seen when treated cultures were examined with the anti-Tac monoclonal antibody. At 24 hr this effect was contrastingly not seen for the OKT-8 marker, although a slight decrease in OKT-4-positive cells was seen. Serotonin thus produced an inhibition of lectin-stimulated lymphocyte proliferation via a mechanism independent of IL-2 production, and caused a decrease in the expression and distribution of IL-2 receptors on the surface of responder cells. | lld:pubmed |
| pubmed-article:6423289 | pubmed:language | eng | lld:pubmed |
| pubmed-article:6423289 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6423289 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:6423289 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6423289 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6423289 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6423289 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6423289 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6423289 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6423289 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6423289 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:6423289 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:6423289 | pubmed:issn | 0008-8749 | lld:pubmed |
| pubmed-article:6423289 | pubmed:author | pubmed-author:SlausonD ODO | lld:pubmed |
| pubmed-article:6423289 | pubmed:author | pubmed-author:de WeckA LAL | lld:pubmed |
| pubmed-article:6423289 | pubmed:author | pubmed-author:WangYY | lld:pubmed |
| pubmed-article:6423289 | pubmed:author | pubmed-author:KristensenFF | lld:pubmed |
| pubmed-article:6423289 | pubmed:author | pubmed-author:WalkerCC | lld:pubmed |
| pubmed-article:6423289 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:6423289 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:6423289 | pubmed:volume | 84 | lld:pubmed |
| pubmed-article:6423289 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:6423289 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:6423289 | pubmed:pagination | 240-52 | lld:pubmed |
| pubmed-article:6423289 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:6423289 | pubmed:meshHeading | pubmed-meshheading:6423289-... | lld:pubmed |
| pubmed-article:6423289 | pubmed:meshHeading | pubmed-meshheading:6423289-... | lld:pubmed |
| pubmed-article:6423289 | pubmed:meshHeading | pubmed-meshheading:6423289-... | lld:pubmed |
| pubmed-article:6423289 | pubmed:meshHeading | pubmed-meshheading:6423289-... | lld:pubmed |
| pubmed-article:6423289 | pubmed:meshHeading | pubmed-meshheading:6423289-... | lld:pubmed |
| pubmed-article:6423289 | pubmed:meshHeading | pubmed-meshheading:6423289-... | lld:pubmed |
| pubmed-article:6423289 | pubmed:meshHeading | pubmed-meshheading:6423289-... | lld:pubmed |
| pubmed-article:6423289 | pubmed:meshHeading | pubmed-meshheading:6423289-... | lld:pubmed |
| pubmed-article:6423289 | pubmed:meshHeading | pubmed-meshheading:6423289-... | lld:pubmed |
| pubmed-article:6423289 | pubmed:meshHeading | pubmed-meshheading:6423289-... | lld:pubmed |
| pubmed-article:6423289 | pubmed:meshHeading | pubmed-meshheading:6423289-... | lld:pubmed |
| pubmed-article:6423289 | pubmed:meshHeading | pubmed-meshheading:6423289-... | lld:pubmed |
| pubmed-article:6423289 | pubmed:meshHeading | pubmed-meshheading:6423289-... | lld:pubmed |
| pubmed-article:6423289 | pubmed:meshHeading | pubmed-meshheading:6423289-... | lld:pubmed |
| pubmed-article:6423289 | pubmed:meshHeading | pubmed-meshheading:6423289-... | lld:pubmed |
| pubmed-article:6423289 | pubmed:year | 1984 | lld:pubmed |
| pubmed-article:6423289 | pubmed:articleTitle | Mechanisms of serotonin-induced lymphocyte proliferation inhibition. | lld:pubmed |
| pubmed-article:6423289 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:6423289 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6423289 | lld:pubmed |
